Small Pharma Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DMTTF research report →
Companywww.smallpharma.com
Small Pharma Inc. , a biotechnology company, focuses on developing short-acting psychedelics with therapy for the treatment of mental health conditions. Its clinical program is N,N-dimethyltryptamine assisted therapy to treat major depressive disorder.
- CEO
- George Tziras
- IPO
- 2021
- HQ
- London, GB
Price Chart
Valuation
- Market Cap
- $37.51M
- P/E
- -2.16
- P/S
- 0.00
- P/B
- 2.88
- EV/EBITDA
- -1.37
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -78.43%
- ROIC
- -128.32%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-22,836,213 · -2.56%
- EPS
- $-0.07 · 0.70%
- Op Income
- $-24,680,068
- FCF YoY
- -36.88%
Performance & Tape
- 52W High
- $0.19
- 52W Low
- $0.04
- 50D MA
- $0.09
- 200D MA
- $0.07
- Beta
- 0.85
- Avg Volume
- 109.35K
Get TickerSpark's AI analysis on DMTTF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our DMTTF Coverage
We haven't published any research on DMTTF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate DMTTF Report →